Healthcare

That regulatory step sits against a tight balance sheet. According to its Appendix 4C released on 29 October 2026, Vectus held $410,000 in cash at 30 September, enough for about 1.33 quarters at the latest rate of spending, before counting an R&D tax refund …

Almost all of the company's newBusinessin the quarter came from outside aged care: Aboriginal community controlled health organisations, workplace emergency response, the resources sector and a US reseller. Visionflex says its priority is to turn these mostly hardware sales into recurring subscriptions. It is …

Its recent announcements combine clinical progress with a new funding model. On 19 October 2026 Invion said it had closed recruitment in its Phase I non-melanoma skin cancer trial and would advance to Phase II. Two days later it announced co-funding and financing agreements …

The company says a research and development tax incentive (RDTI) forward financing facility is expected in the December 2026 quarter and that it intends to raise capital, with timing and structure not yet set. Until then, its candidates sit at Phase 1 completion and …

That short runway sits alongside management commentary describing an active project pipeline. Whether Oakridge can convert that pipeline into cash receipts quickly enough, or secure additional funding, is the question its board has flagged and shareholders may raise at theAnnual General Meetingon 27 November …

The financial side is less comfortable. Cash fell to about $712,000 at 30 September 2026 after net operating outflows of $559,000. The company's reported funding runway of 26.32 quarters depends almost entirely on $14 million of undrawn capacity under a redeemable convertible note facility, …

Since then it has drawn new money. On 30 October Adherium announced an additional $750,000Unsecured Loanfacility from Barvest Ventures, a Trudell-related investor, on top of a $700,000 Barvest facility received on 7 October. The company also received a $257,917 milestone payment from AstraZeneca on …